Cargando…

TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive decline in lung function. Fibrotic diseases, such as IPF, are characterized by uncontrolled activation of fibroblasts. Since the microenvironment is known to affect cell behavior,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Epstein Shochet, Gali, Brook, Elizabetha, Bardenstein-Wald, Becky, Shitrit, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029598/ https://www.ncbi.nlm.nih.gov/pubmed/32070329 http://dx.doi.org/10.1186/s12931-020-1319-0

Ejemplares similares

Integrin alpha-5 silencing leads to myofibroblastic differentiation in IPF-derived human lung fibroblasts
por: Shochet, Gali Epstein, et al.
Publicado: (2020)

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2017)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression
por: Moshkovitz, Noa, et al.
Publicado: (2023)

Galectin-3 levels are elevated following nintedanib treatment
por: Shochet, Gali Epstein, et al.
Publicado: (2020)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—Approaching with Next-Generation Sequencing and Bioinformatics
por: Chang, Wei-An, et al.
Publicado: (2020)

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
por: Kaunisto, Jaana, et al.
Publicado: (2019)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
por: Krauss, Ekaterina, et al.
Publicado: (2019)

mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts
por: Romero, Yair, et al.
Publicado: (2016)

αAzithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
por: Krempaska, Kristina, et al.
Publicado: (2020)

Correction to: Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
por: Krempaska, Kristina, et al.
Publicado: (2020)

The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—A Next-Generation Sequencing and Bioinformatic Approach
por: Tsai, Ming-Ju, et al.
Publicado: (2019)

Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale
por: Wand, Ori, et al.
Publicado: (2020)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
por: Leuschner, Gabriela, et al.
Publicado: (2020)

Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis
por: Nie, Yun-Juan, et al.
Publicado: (2022)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)
por: Colunga Biancatelli, Ruben Manuel Luciano, et al.
Publicado: (2020)

Serum Procalcitonin in Patients With Combined Lung Cancer and Idiopathic Pulmonary Fibrosis (LC-IPF)
por: Mohamed, Sherif, et al.
Publicado: (2020)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
por: Confalonieri, Paola, et al.
Publicado: (2022)

TRIB3 Mediates Fibroblast Activation and Fibrosis though Interaction with ATF4 in IPF
por: Wang, Lan, et al.
Publicado: (2022)

TGF beta inhibits HGF, FGF7, and FGF10 expression in normal and IPF lung fibroblasts
por: Correll, Kelly A., et al.
Publicado: (2018)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

Epigenetic regulation of IPF fibroblast phenotype by glutaminolysis
por: Xiang, Zheyi, et al.
Publicado: (2022)

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
por: Boon, Kathy, et al.
Publicado: (2009)

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
por: Ferrara, Giovanni, et al.
Publicado: (2016)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
por: Cherrez-Ojeda, Iván, et al.
Publicado: (2018)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nu16fs2v8s09jagueqodtkc2l2